Founded in 2014, Medera is a clinical-stage company dedicated to next-generation cell and gene therapies for difficult-to-treat and incurable diseases. Medera’s preclinical and clinical programs target a range of cardiac, vascular and muscular indications, including Heart Failure with preserved Ejection Fraction (HFpEF), Duchenne Muscular Dystrophy and Pulmonary Hypertension, etc. Medera operates via its 2 subsidiaries: Novoheart (www.linkedin.com/company/novoheart-limited) is responsible for Disease Modelling & Drug Discovery using our proprietary, award-winning mini-Heart Technology, which offers a range of bioengineered human heart constructs including the world’s first human heart-in-a-jar as healthy and diseased human hearts for testing toxicity and efficacy. This platform enables us to uniquely model human-specific diseases and discover therapeutic candidates all in the context of human cells and tissues, free from species-specific differences. Before privatisation by Medera, Novoheart was dually listed on the Toronto Stock Exchange and Frankfurt Stock Exchange. Sardocor (www.linkedin.com/company/sardocor) is dedicated to the clinical development of novel therapies. Building upon Novoheart’s bioengineered human tissue-based assays for disease modelling and drug discovery, Sardocor aspires to create the shortest regulatory path to the clinic for advancing effective next-generation cell & gene therapy.
View Top Employees from Medera Inc.Website | https://www.medera.bio |
Employees | 13 (7 on RocketReach) |
Address | 6 Tide St 2nd Floor, Boston, Massachusetts 02210, US |
Industry | Biotechnology Research |
Looking for a particular Medera Inc. employee's phone or email?
Ronald Li is the CEO of Medera Inc..
7 people are employed at Medera Inc..
Medera Inc. is based in Boston, Massachusetts.